Heron Therapeutics (HRTX) Current Assets (2010 - 2026)

Heron Therapeutics has reported Current Assets for 17 years, with the latest figure at $229.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 7.58% year-over-year to $229.0 million; the trailing twelve-month figure through Mar 2026 stood at $229.0 million (up 7.58% YoY), and the FY2025 full-year result was $238.1 million, up 13.9% from the prior year.
• Current Assets for Q1 2026 stood at $229.0 million, down from $238.1 million in the prior quarter.
• The five-year high for Current Assets was $238.1 million in Q4 2025, with the low at $165.3 million in Q2 2023.
• Historically, Current Assets has averaged $204.3 million across 5 years, with a median of $205.4 million in 2022.
• Annual changes were most pronounced in 2022 — Current Assets plunged 47.06% — and 2025, when it gained 17.53%.
• Heron Therapeutics' Current Assets stood at $205.4 million in 2022, then dropped by 8.11% to $188.8 million in 2023, then advanced by 10.72% to $209.0 million in 2024, then grew by 13.9% to $238.1 million in 2025, then declined by 3.81% to $229.0 million in 2026.
• The last three Current Assets figures came in at $229.0 million (Q1 2026), $238.1 million (Q4 2025), and $229.4 million (Q3 2025), per Business Quant data.